Key Takeaways

  • Billy Evans attempted to secure back-end points on a movie deal to route family earnings away from Elizabeth Holmes's court-mandated investor restitution debt.
  • John Coogan rejected a private pitch from Evans proposing a "Theranos 2.0" redemption arc, demanding verified biotech domain knowledge instead of public relations polish.
  • Jordi Hays pointed out that legitimate diagnostic companies like GeneWeave succeeded through verified science, while Holmes never demonstrated real technical focus.
  • Holmes and Sunny Balwani held all their equity through an $11 billion peak valuation without executing secondary sales to extract personal liquidity.
  • Late-stage founders avoiding market panic while cashing out tens of millions rely on The Debt-Backed Secondary Sale Trick.

The Debt-Backed Secondary Sale Trick

When Elizabeth Holmes built Theranos into an $11 billion paper giant, she missed the most basic lesson of late-stage company building: taking money off the table. As Jordi Hays noted on TBPN, Holmes operated as the “least shrewd person in the world potentially,” adding, “No secondary selling 11 billion doing fraud purely for the love of the game.” Neither Holmes nor Sunny Balwani pulled cash out of secondary share sales. Now, Holmes faces hundreds of millions of dollars in investor restitution. Her partner Billy Evans is left attempting financial gymnastics, seeking back-end movie points to keep earnings away from her creditors. As John Coogan explained, “Because she claimed in the show she has hundreds of millions of dollars of restitution to pay. So of course, even if she wanted to make money on it, she wouldn't get any benefit of it.” Hays added that Evans likely wanted “to get those profits and then use that for their kids and their family, but then it doesn't flow to her bank account, which immediately gets grabbed by the investors.”

When Evans pitched Coogan on a "Theranos 2.0" rehabilitation tour, Coogan gave him a hard reality check: "Look, if we're going to take this Elizabeth Holmes redemption arc seriously, I want to see some great calls about biotech." Contrast Theranos with real diagnostic exits like GeneWeave, where founders built verifiable clinical machinery. Holmes lacked that technical grounding. Worse for her family, she failed to execute the standard secondary playbook that modern unicorn executives use to secure personal wealth long before an exit.

Founders who want liquidity without signaling panic run a specific financial maneuver:

Step 1: Substantial Personal Debt

You take out a hundred million of debt from a major financial institution.

Step 2: The Secondary Equity Sale

Then you sell secondary equity, sell another 100 million of secondary, and pay off the debt.

Step 3: Personal Debt Repayment Disclosure

Then you can tell everyone, look, I just sold secondary to pay off my personal debt. Everyone assumes, oh, they think it's credit card debt. They don't realize that it was an equity-backed hundred million line of credit from a major financial institution. You don't need to clarify that part, but you can still get away with 100 mil out of the gate.

When This Works (and When It Doesn't)

This maneuver works for unicorn founders leading companies valued in the billions who need to liquidate tens or hundreds of millions of dollars without sending a negative signal to prospective investors. In venture capital, a founder selling equity directly often triggers fears of lost conviction. Converting that liquidation into the narrative of settling personal liabilities protects company valuation and calms the cap table.

It breaks down completely when private market conditions freeze or credit lines mature before secondary buyers clear diligence. If your valuation drops 60% during a venture slowdown, private banks will issue immediate margin calls against your pledged equity. Pledging company stock also creates corporate governance liabilities if your board requires full transparency on related-party loans, or if public S-1 filings expose your personal credit lines to regulatory scrutiny.

What to Do With This

Assume you are a 27-year-old founder holding 25% of a Series C logistics startup recently valued at $200 million, but your personal net worth sits entirely in illiquid stock. You need $3 million to buy a home and clear angel debt, but your lead investor warns that selling common stock will signal cold feet to Series D prospects.

To execute this playbook cleanly this week:

First, approach private wealth lenders at your corporate bank to establish a $3 million personal line of credit pledged against your vested equity.

Second, during your upcoming Series D round, carve out an approved secondary block of $3 million reserved for existing common shareholders, pricing it at the new round's preferred valuation.

Third, once the wire clears, pay down the bank facility within 30 days and report the sale to your board and team as a routine cleanup of early personal liabilities. Frame the transaction as eliminating personal financial distractions so you can commit fully to the multi-year path toward an IPO.